Order matters? study examines drug sequences in advanced bowel cancer
NCT ID NCT06137170
First seen Mar 06, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study looked at past medical records of 121 people with metastatic colorectal cancer (advanced bowel cancer) in Europe. Researchers wanted to see how the order of taking two approved drug combinations—regorafenib and TAS (with or without bevacizumab)—affected treatment length and survival. No new treatments were given; the study simply collected existing data to better understand real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Many Locations
Multiple Locations, France
-
Many Locations
Multiple Locations, Italy
-
Many Locations
Multiple Locations, Spain
Conditions
Explore the condition pages connected to this study.